Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Guardant Health, Inc. - Common Stock (NQ:GH)

67.47 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
From Guardant Health, Inc.
Via Business Wire
RXO, The Ensign Group, LifeStance Health Group, Surgery Partners, and Guardant Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after President Trump criticized the Federal Reserve's approach to interest rate cuts, warning that the pace was slow and could hinder economic growth.... 
Via StockStory
Topics Economy Government World Trade
Earnings Scheduled For February 20, 2025
 
Via Benzinga
3 Reasons to Sell GH and 1 Stock to Buy Instead
What a time it’s been for Guardant Health. In the past six months alone, the company’s stock price has increased by a massive 112%, reaching $44.11 per share. This run-up might have investors... 
Via StockStory
Topics Bankruptcy
3 of Wall Street’s Favorite Stocks Facing Headwinds
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
From Guardant Health, Inc.
Via Business Wire
Reflecting On Testing & Diagnostics Services Stocks’ Q4 Earnings: Guardant Health (NASDAQ:GH)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting... 
Via StockStory
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking NeoGenomics (NASDAQ:NEO)
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the testing & diagnostics services stocks, including NeoGenomics (NASDAQ:NEO) and its peers. 
Via StockStory
3 Small-Cap Stocks in the Doghouse
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
4 Healthcare Stocks With Massive Gains—and More to Come
Healthcare is the top industry of 2025 so far. These healthcare companies have seen 30% increases in share prices since the beginning of the year. 
Via MarketBeat
Topics Artificial Intelligence Economy World Trade
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: Labcorp (NYSE:LH) Vs The Rest Of The Pack
Looking back on testing & diagnostics services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Labcorp (NYSE:LH) and its peers. 
Via StockStory
Q4 Testing & Diagnostics Services Earnings: RadNet (NASDAQ:RDNT) Impresses
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how testing & diagnostics services stocks fared in Q4, starting... 
Via StockStory
Guardant Health’s Shield Blood Test Now Covered for VA Community Care Beneficiaries
From Guardant Health, Inc.
Via Business Wire
1 Healthcare Stock on Our Watchlist and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and... 
Via StockStory
Topics Stocks
Testing & Diagnostics Services Stocks Q4 Recap: Benchmarking Quest (NYSE:DGX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Quest (NYSE:DGX) and the best and worst... 
Via StockStory
1 Stock Under $50 with Solid Fundamentals and 2 to Turn Down
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision. 
Via Benzinga
Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
From Guardant Health, Inc.
Via Business Wire
Healthcare Stocks Doing Well But SMID Biotech Looking A Little Frazzled
Small caps took another step down this past week as geopolitical events dampened sentiment. 
Via Talk Markets
Topics ETFs Stocks / Equities
Guardant Health Joins Forces With Dak Prescott’s Faith Fight Finish Foundation and Feist-Weiller Cancer Center’s Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities
From Guardant Health, Inc.
Via Business Wire
Guardant Health’s (NASDAQ:GH) Q4: Beats On Revenue
Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 30.2% year on year to $201.8 million. Its GAAP loss of $0.90 per share was 12.4%... 
Via StockStory
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
From Guardant Health, Inc.
Via Business Wire
What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?
Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials. 
Via Benzinga
Guardant Health Tops Q4 Revenue Forecast
The oncology testing specialist reported strong top-line growth, but also rising costs and ongoing net losses. 
Via The Motley Fool
Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.